Form 4: Oscar Health CEO Granted 1.6M Restricted Stock Units

Oscar Health's CEO, Mark T. Bertolini, was granted 1,596,877 restricted stock units vesting over three years starting March 2027.

Summary

• Mark T. Bertolini, Chief Executive Officer and Director of Oscar Health, Inc. (OSCR), was granted 1,596,877 shares of Class A Common Stock.
• These shares represent restricted stock units (RSUs) with a transaction date of March 2, 2026.
• The RSUs will vest in three equal annual installments, with the first installment commencing on March 2, 2027.
• Vesting is contingent upon Mr. Bertolini's continued employment as Chief Executive Officer or service as a member of the Board of Directors through the applicable vesting dates.
• Following this transaction, Mr. Bertolini beneficially owns 4,463,543 shares directly, which includes shares to be issued from the vesting of one or more restricted stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating the company's commitment to retaining its CEO and aligning his long-term interests with shareholder value through a significant equity grant.

Positives

• The grant of restricted stock units aligns management's interests with long-term shareholder value through equity ownership.
• The multi-year vesting schedule encourages the retention of a key executive (CEO and Director) over a significant period.

Negatives

• The acquisition price for the restricted stock units was $0, indicating a grant rather than an open market purchase by the insider.

Risks

• The vesting of these restricted stock units is subject to the CEO's continued employment or service, meaning unvested units would be forfeited if he departs before the vesting dates.

Future Outlook

The grant of restricted stock units with a multi-year vesting schedule indicates a long-term commitment by the company to retain its Chief Executive Officer and align his incentives with future company performance.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units with time-based vesting, are a standard practice in the healthcare technology sector to incentivize executive retention and align leadership interests with long-term shareholder value. This grant to Oscar Health's CEO is consistent with typical executive compensation structures seen across the industry.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a significant component of executive compensation is a common practice among publicly traded health technology companies, similar to those observed at peers like Teladoc Health (TDOC) or Amwell (AMWL).
• The multi-year vesting schedule (three equal annual installments) is standard for long-term incentive plans, aiming to retain key executives and ensure sustained performance, comparable to vesting schedules at companies such as UnitedHealth Group (UNH) for their executive equity awards.
• The size of the grant (1.6 million shares) for a CEO of a company like Oscar Health would typically be evaluated against market capitalization, company performance, and peer group compensation data to determine its competitiveness and appropriateness.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term stock performance.
• Employees: No direct impact mentioned, but a stable leadership team can positively influence employee morale and strategic direction.

Next Steps

• First vesting installment of restricted stock units on March 2, 2027.
• Subsequent annual vesting installments on March 2, 2028, and March 2, 2029 (implied by 'three equal annual installments').

Key Dates

Recommendation

This Form 4 reports a standard equity grant to the CEO, which is generally a positive sign for executive retention and alignment of interests. However, it does not provide new financial performance data or strategic shifts that would warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position, acknowledging the stability in leadership incentives without indicating a significant change in the company's fundamental outlook based solely on this filing.

Keywords

Oscar Health, OSCR, Mark T. Bertolini, Restricted Stock Units, RSU, Insider Transaction, CEO Compensation, Equity Grant, Form 4